Background: Chronic obstructive pulmonary disease (COPD), a largely preventable and manageable respiratory condition, affects an estimated 12% to 20% of adults. Long-acting inhaled ␤-agonists and anticholinergics have both been shown to improve COPD outcomes and are recommended for moderate to severe disease; however, little is known about their comparative effectiveness.
C
hronic obstructive pulmonary disease (COPD) is a largely preventable and manageable respiratory condition that affects an estimated 12% to 20% of adults older than 40 years (1, 2) . It is also the fifth leading cause of death in the world and is projected to be the fourth by 2030 (3, 4) . Thus, effective, evidence-based strategies to improve COPD outcomes are crucial.
Medications are a mainstay of COPD management. Long-acting ␤-agonists, such as salmeterol and formoterol, and long-acting anticholinergics, also referred to as "muscarinic antagonists" (of which only tiotropium bromide is currently available for public use), are recommended for the management of moderate to severe COPD (5) . Randomized, controlled trials (RCTs) (6, 7) have shown that both types of drug can decrease exacerbations and hospitalizations and improve symptoms, lung function, quality of life, and possibly mortality compared with placebo. However, little is known about their comparative effectiveness in actual practice. This information would allow patients to initiate therapy with the long-acting medication most likely to provide the greatest benefit, and possibly avoid use of additional medications that would increase risk, inconvenience, and cost (5).
The purpose of our population-based, retrospective, observational cohort study of older patients with COPD was to compare the effectiveness of long-acting anticholinergics and long-acting ␤-agonists in terms of survival. Older patients were studied because they carry the highest burden of COPD and because population-wide medication records were available for patients aged 65 years or older.
METHODS
We conducted our study by using health administrative data from Ontario, a province of Canada with a di-the 2001, 2003, and 2005 surveys were linked to the health administrative databases on an individual level to obtain additional patient information, including smoking history.
Study Population
We included patients who met a previously validated case definition of physician-diagnosed COPD on the basis of health administrative data (9) , were aged 66 years or older, and filled a first prescription for either a long-acting anticholinergic or long-acting ␤-agonist between 1 July 2003 (when long-acting anticholinergics were first commonly used in the community) and 31 March 2007. Compared with real-world clinical evaluation by a physician (which may or may not have included spirometry [10] ), the case definition of 1 hospitalization or 3 ambulatory care claims for COPD had a positive predictive value of 81.3% in adults aged 35 years or older (9) and 86.3% in adults aged 65 years or older (unpublished data). This value was probably even higher in patients who met the case definition and were prescribed a long-acting anticholinergic or long-acting ␤-agonist, such as those studied here. The date of filling a first prescription was used as the study index date. Only new users, defined as those who had not filled a prescription for a long-acting anticholinergic or long-acting ␤-agonist in the previous 12 months (including a combination medication that contained a long-acting ␤-agonist), were included to avoid bias due to either better outcomes among patients who had been receiving their index medication for a longer time or worse outcomes among patients who had been receiving therapy with other long-acting medications that had failed. The study was restricted to patients aged 66 years or older to allow us to look at medication use in the past year.
Baseline Characteristics
We obtained demographic, COPD-related, and general care-related characteristics from the health administrative databases ( Table 1 and Appendix Table 1 , available at www.annals.org). Severity of COPD was captured by using information from hospitalizations, emergency department visits, ambulatory care visits, prescription drug use, and interventions before the index date. Socioeconomic status was inferred from neighborhood income, which was derived from postal code and census data (11) . Comorbidity was based on diagnostic information in health services records from the 2 years before the index date and was characterized by using the Johns Hopkins Adjusted Clinical Group Case-Mix System (12, 13) .
Outcome Measures
The primary outcome was all-cause mortality. Secondary outcomes were hospitalizations and emergency department visits for COPD, related respiratory diseases (influenza, acute bronchitis, or pneumonia), and cardiovascular disease (acute myocardial infarction, congestive heart failure, ischemic heart disease, cardiac arrhythmias, or cerebrovascular disease). Hospitalizations and emergency de-
Context
Long-acting inhaled ␤-agonists and anticholinergic agents are both used to treat chronic obstructive pulmonary disease (COPD). Whether one or the other is better for initial therapy is not known.
Contribution
Patients with physician-diagnosed COPD were identified in a public health administrative database by using a computer algorithm. Patients initially prescribed a long-acting anticholinergic agent had more hospital visits and higher mortality rates than those initially prescribed a long-acting ␤-agonist.
Caution
Patients were identified as having COPD according to administrative data, not clinical guidelines. Lung function testing was not available.
Implication
Further study regarding the relative benefits of long-acting anticholinergics and ␤-agonists for treatment of COPD is warranted.
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Original Research Long-Acting ␤-Agonists and Long-Acting Anticholinergics in COPD partment visits were analyzed as a combined end point with mortality because mortality was common and the factors that caused it were probably exacerbations of those that caused a hospitalization or emergency department visit (making censoring for mortality inappropriate). Patients were followed beginning 7 days after their index prescription, to allow time for patients to start taking their medication and for it to start taking effect (14) . Patients who did not die were censored on 15 March 2009. All-cause mortality was used because cause of death was not available in the health administrative data.
Propensity Score Matching and Analysis
We used propensity score matching to compare patients with similar observed characteristics, all of whom were potential candidates for both treatments (15) . Patients initially prescribed a long-acting anticholinergic were matched 1:1 with those initially prescribed a long-acting ␤-agonist on the basis of age (Ϯ1 year), sex, asthma status, number of COPD medication prescriptions filled in the previous year, and propensity score. An absolute standardized difference between variables of less than 10% was accepted as adequate balance (16) .
Outcomes were compared by using Cox proportional hazards regression analysis, adjusted for matched pairs. All statistical tests were 2-sided, with statistical significance defined as a P value less than 0.05. Analyses were performed by using SAS, version 9.1 (SAS Institute, Cary, North Carolina). The Appendix (available at www.annals.org) contains additional information on propensity score methodology.
To further ensure that variables not available in the health administrative data, including smoking status, were balanced between treatment groups, we performed a sensitivity analysis by using propensity score calibration and additional information from the Canadian Community Health Survey (17) (Appendix).
Additional Sensitivity Analyses
We conducted several sensitivity analyses to evaluate the robustness of our results. The main analyses were repeated by using a standard proportional hazards regression that adjusted for all covariates, rather than matching on the propensity score. A complementary analysis, which compared the on-treatment effects of long-acting ␤-agonists and long-acting anticholinergics, was also conducted on the basis of current patient use of these medications rather than initial choice of treatment. This was done with a time-on-treatment analysis of the effect of medication exposure by using a standard time-varying proportional hazards analysis with adjustments for all of the variables used to calculate the propensity score.
The propensity score-matched analyses were also repeated on subsets of the cohort to look for consistency in the results. First, we examined the subsets of the cohort who had or had not previously received spirometry, to determine whether more or less certainty about the COPD † Testing the hypothesis of no difference between the 2 medication cohorts. ‡ In Ontario, primary care is provided by family and general physicians, and specialist COPD care is usually provided by pulmonologists, general internists, or geriatricians. § Number of prescriptions for long-or short-acting ␤-agonists, long-or short-acting anticholinergics, inhaled corticosteroids, oral corticosteroids, methylxanthine, or respiratory antibiotics. Pneumonia, influenza, or acute bronchitis. ¶ Acute myocardial infarction, congestive heart failure, ischemic heart disease, cardiac arrhythmia, or cerebrovascular disease.
Original Research Long-Acting ␤-Agonists and Long-Acting Anticholinergics in COPD diagnosis influenced the results. The original analysis was also stratified by factors of a priori interest, including sex, asthma status, number of prescriptions for COPD medication filled in the previous year, inhaled corticosteroid use, and diagnosis of congestive heart failure. We conducted 2 sensitivity analyses to check assumptions made in the main analyses. One was that follow-up should not begin until 7 days after filling the index prescription, to allow time for patients to start taking their medication and for the medication to start taking effect. To check this, we repeated the analysis, including outcomes that occurred within this period. Another assumption was that hospitalizations and emergency department visits were along the causal pathway to the primary outcome of death and therefore should be combined with it as a composite outcome. To check this, we examined time to first COPD hospitalization and time to first COPD emergency department visit as separate outcomes.
Finally, we determined whether it was plausible that an unmeasured confounder or the inclusion of persons without COPD, due to misclassification error, was responsible for the observed results by using an array approach. The rate ratio of a theoretical, unmeasured confounder and the imbalance of this confounder between the study cohorts were both varied to see at what point the observed hazard ratio was reduced to 1.0 (18). The same approach was used to estimate the effects of misclassification due to the case definition (Appendix).
Role of the Funding Source
Our study was funded by the Government of Ontario and the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. The funding sources had no role in study design, collection, analysis, interpretation of data, writing of the report, or the decision to submit the report for publication.
RESULTS
We found 28 563 new users who were initially prescribed a long-acting anticholinergic and 17 840 who were initially prescribed a long-acting ␤-agonist and met the validated case definition of COPD, on the basis of the health administrative data (Appendix Figure, available at www.annals.org). Compared with users of long-acting ␤-agonists, users of long-acting anticholinergics were less likely to be female or have asthma and less likely to have filled a prescription for a respiratory antibiotic or oral corticosteroid in the previous year, seen a specialist, or received spirometry ( Table 1) .
Propensity Score Matching
The propensity score provided fair discrimination between treatment groups (c statistic ϭ 0.66). Matching produced 15 532 pairs. After matching, the long-acting anticholinergic and long-acting ␤-agonist groups did not significantly differ ( Table 1 and Appendix Table 2 , available at www.annals.org). Within the matched cohorts, median follow-up times for patients initially prescribed longacting anticholinergics or long-acting ␤-agonists were 3.2 and 3.3 years, respectively (maximum, 5.5 years). Overall, 39.9% of patients initially prescribed a long-acting anticholinergic and 36.5% of patients initially prescribed a long-acting ␤-agonist died during the follow-up period ( Table 2 ). Appendix Table 3 (available at www.annals.org) shows absolute survival by year. The Figure shows survival, by initially prescribed medication.
Overall, patients who were initially prescribed a long-acting anticholinergic had a modest but significantly higher adjusted rate of death (adjusted hazard ratio, 1.14 [95% CI, 1.09 to 1.19] ) and all other outcomes than those prescribed a long-acting ␤-agonist ( Table 2 ). No evidence indicated that the hazard ratios changed over time. The results of the calibrated propensity score analysis were consistent with those of the main analysis (Appendix).
Additional Sensitivity Analyses
The results from the standard proportional hazards regression models that included all of the covariates were similar to the results from the propensity score models ( Table 2 ). The time-on-treatment analysis similarly found that patients currently receiving a long-acting anticholinergic were significantly more likely to die than those currently receiving a long-acting ␤-agonist, which confirms our main results ( Table 3) .
Separate analyses of patients who had or had not received previous spirometry found no significant difference in results between these subsets ( Table 4 ). An initial prescription for long-acting ␤-agonists was also consistently associated with improved survival when results were stratified by sex, asthma status, inhaled corticosteroid use, congestive heart failure, and number of prescriptions for COPD medication filled in the previous year (Appendix Table 4 , available at www.annals.org). Of interest, stratification by number of prescriptions for COPD medication suggested that the relative survival of those initially treated with a long-acting ␤-agonist, compared with a long-acting anticholinergic, may have been higher in patients with fewer prescriptions (hazard ratio for those with 0 to 2 prescriptions, 1.23 [CI, 1.13 to 1.33]; 3 to 10 prescriptions, 1.14 [CI, 1.06 to 1.23]; Ͼ10 prescriptions, 1.07 [CI, 1.00 to 1.15] ).
An initial prescription for a long-acting ␤-agonist continued to be associated with better outcomes than one for a long-acting anticholinergic when the analysis was repeated, first with the inclusion of outcomes that occurred within 7 days of the index prescription being filled and then with COPD hospitalizations and emergency department visits for COPD analyzed as separate outcomes
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The rate ratio of a theoretical, unmeasured potential confounder would have to be at least 2.0, or the imbalance due to this confounder more than 15%, to reduce the observed hazard ratio to 1.0. Likewise, if all patients who were misclassified as having COPD were in the long-acting ␤-agonist group and were 30% less likely to die than those with true COPD, or if they were all in the long-acting anticholinergic group and were at least 30% more likely to COPD ϭ chronic obstructive pulmonary disease. * Time until 50% of patients experienced the event. Estimated rates were derived from paired Kaplan-Meier curves. † Reflects the risk in the long-acting anticholinergic cohort compared with the long-acting ␤-agonist cohort. Hazard ratios are adjusted for membership in a matched pair. Members of the long-acting anticholinergic and long-acting ␤-agonist cohorts were matched by using propensity score, age, sex, asthma status, and number of COPD medications. ‡ Testing the hypothesis that the hazard ratio is 1.00. § Reflects the risk in the long-acting anticholinergic cohort compared with the long-acting ␤-agonist cohort. Hazard ratios are adjusted for all variables. Time until 25% of patients experienced the event (25th percentile). Because fewer than one half of patients died or were hospitalized, the median time to these outcomes could not be estimated. ¶ Pneumonia, influenza, or acute bronchitis. ** Acute myocardial infarction, congestive heart failure, ischemic heart disease, cardiac arrhythmia, or cerebrovascular disease.
† † Time until 10% of patients experienced the event (10th percentile). Because so few patients visited the emergency department, the median time to this outcome could not be estimated.
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DISCUSSION
We conducted an observational, longitudinal, population-based study of new use of long-acting anticholinergics and long-acting ␤-agonists by older patients who met a validated case definition of COPD on the basis of health administrative data. Patients who were initially prescribed a long-acting anticholinergic seemed to have a 14% higher adjusted mortality rate than those initially prescribed a long-acting ␤-agonist and were also more likely to be hospitalized or to visit an emergency department for COPD or a related condition. The incremental risk associated with long-acting anticholinergics seemed to be independent of patient sex or coexisting medical conditions or whether the diagnosis of COPD was confirmed with spirometry. Thus, our findings suggest that long-acting ␤-agonists may be more effective than long-acting anticholinergics at improving survival in older patients with COPD. To our knowledge, our observational study is the first to directly compare mortality with long-acting ␤-agonists and mortality with long-acting anticholinergics in a large population of older patients with COPD.
A few small RCTs and meta-analyses that compared such outcomes as lung function or health status between patients receiving long-acting ␤-agonists and those receiving long-acting anticholinergics have yielded conflicting results. However, most found that both drug classes were equally effective in preventing exacerbations and hospitalizations (19 -22). A larger RCT designed to examine the relative efficacy of long-acting ␤-agonists versus longacting anticholinergics on exacerbations (but not mortality, as in our study) has been completed (23), but the results have not yet been released.
Although RCTs remain the gold standard for the study of the efficacy of COPD medication, observational studies, such as ours, provide complementary information on medication effectiveness (which might differ from RCT results) for several reasons. First, RCTs often have limited generalizability because they exclude patients who are part of the population to which the therapy will be applied, such as those with severe disease or comorbidity (24). For example, our study examined a large, older, frailer population-many of whom would have been excluded from previous RCTs. Second, RCTs may recruit patients who are not new users of medications (more than one half of the patients enrolled in the TORCH [TOwards a Revolution in COPD Health] trial [7] , which studied the effectiveness of inhaled cortico- Long-acting β-agonist
Long-acting anticholinergic
Log-rank P < 0.001 COPD ϭ chronic obstructive pulmonary disease. * We treated time spent receiving long-acting anticholinergics or long-acting ␤-agonists as time-dependent covariates. The hazard ratio compares the risk of patients currently receiving a long-acting anticholinergic with that of patients currently receiving a long-acting ␤-agonist. Hazard ratios are adjusted for the covariates used to calculate the propensity score. † Testing the hypothesis that the hazard ratio is 1.00. ‡ Pneumonia, influenza, or acute bronchitis. § Congestive heart failure, ischemic heart disease (including acute myocardial infarction), cardiac arrhythmia, or cerebrovascular disease.
steroids and long-acting ␤-agonists, had used at least 1 of these medications in the year before study entry) and who, because they tolerated the regimen and volunteered to receive it in a study, may be more likely to have favorable outcomes. To avoid this, we examined only new users of medication. Finally, RCTs are often not large enough or long enough to look at relatively rare events, such as mortality. Our study followed tens of thousands of patients for up to 5.5 years. Our study suggests a relative difference in mortality between patients initially prescribed long-acting anticholinergics and those prescribed long-acting ␤-agonists, but it was not designed to determine the reasons why. One possibility is that both types of drug effectively reduce mortality, but long-acting ␤-agonists do so more than long-acting anticholinergics. A second possibility is that long-acting ␤-agonists do not or only marginally reduce mortality, whereas long-acting anticholinergics increase mortality. The latter hypothesis is supported by several studies and meta-analyses (25-30), which found an increase in allcause and cardiovascular mortality associated with inhaled anticholinergics but not with inhaled ␤-agonists. However, few of these studies focused specifically on long-acting (as opposed to short-acting) medications. In contrast, a recent meta-analysis (6, 31), which included the large UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) study, found no evidence of increased mortality associated with long-acting anticholinergics; however, this work has the same limitations as the RCTs it was based on, most notably limited generalizability and the inclusion of patients who had previously received the study medications.
Our study has limitations. First, a drawback of all observational studies is potential confounding by indication or by disease severity. Because our data did not contain a precise measure of disease severity (such as lung function), we cannot be sure that such confounding did not occur. However, we consider confounding unlikely because we controlled for many prognostically important variables. As further assurance that an unmeasured confounder, such as smoking, was accounted for, a propensity score calibration analysis was used to confirm the results. In addition, a potential unmeasured confounder would have to have either a much greater association with death than that of smoking or a greater imbalance between the cohorts than that seen for any of the variables except asthma to negate our results (32). Such a confounder also could not be strongly correlated with any of the other variables (such as asthma) already adjusted for in the analysis.
Second, cases of other respiratory diseases, most likely asthma, could have been misclassified as COPD. In an extreme scenario in which all such misclassification occurred in the long-acting ␤-agonist group, patients incorrectly classified as having COPD would have had to be about 30% less likely to die than those with true COPD to explain our results. Because all-cause mortality has been estimated to be 27% lower in patients aged 65 years or older with asthma than in patients of the same age with COPD ϭ chronic obstructive pulmonary disease. * Reflects the risk in the long-acting anticholinergic cohort compared with the long-acting ␤-agonist cohort. Hazard ratios are adjusted for membership in a matched pair.
Members of the long-acting anticholinergic and long-acting ␤-agonist cohorts were matched by using propensity score, age, sex, asthma status, and number of COPD medications. † Testing the hypothesis that the hazard ratio is 1.00. ‡ Testing the hypothesis that the ratio of the hazard ratios is 1.00. § Pneumonia, influenza, or acute bronchitis. Congestive heart failure, ischemic heart disease (including acute myocardial infarction), cardiac arrhythmia, or cerebrovascular disease.
Original Research Long-Acting ␤-Agonists and Long-Acting Anticholinergics in COPD COPD (2, 33), misclassification could explain our observed results. In a second extreme scenario, in which misclassification only occurred in the long-acting anticholinergic group, patients misclassified as having COPD would have had to be about 30% more likely to die than those with true COPD to explain our results. If the misclassified patients had asthma, mismanagement of their disease could have increased their risk for death. However, this is unlikely to have caused a 30% increase in mortality in practice, especially because a large proportion of patients receiving a long-acting anticholinergic were also receiving asthma medications, and long-acting anticholinergics seem to benefit patients with asthma (34). Because the medication groups were matched on a codiagnosis of asthma, neither extreme scenario is likely. Finally, patients were not completely adherent to their index medication regimen and often received the other study medication, a situation that is common in the real world. However, the results of a time-varying analysis, which looked only at current use of medication, were consistent with our main results and, on average, patients spent more time taking the initially prescribed drug than taking the alternative (Appendix).
In summary, we conducted a population-based, retrospective, observational study of new use of long-acting anticholinergics and long-acting ␤-agonists in older patients who met a validated case definition of COPD on the basis of health administrative data. We found that patients initially prescribed a long-acting anticholinergic seemed to have a 14% higher adjusted mortality rate than those initially prescribed a long-acting ␤-agonist. This suggests that long-acting ␤-agonists might be a better initial therapy for patients with moderate to severe COPD. Future research is needed to confirm these findings in RCTs and in younger patients. Research is also needed to examine the relative safety profiles of these medications so that their riskbenefit ratios can be compared. Stop by the ACP/Annals booth and register to be a peer reviewer or discuss your thoughts for submissions or topic coverage with Annals staff.
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APPENDIX: EFFECTIVENESS OF LONG-ACTING INHALED ␤-AGONISTS AND ANTICHOLINERGICS IN OLDER PATIENTS WITH COPD

Cohort Assembly
The Appendix Figure shows how patients in the administrative health databases were selected for inclusion in our study.
Propensity Score Analysis
We used propensity score methodology to control for confounding by baseline cohort characteristics. The propensity score reflects the probability that a given patient was initially prescribed a long-acting anticholinergic, given that patient's particular pattern of baseline covariates, and was calculated by using logistic regression. A set of 57 covariates, which covered patient demographic characteristics, COPD severity, and overall health, were used to calculate the propensity score. Appendix Table 1 shows the variables used and the associated odds ratios.
One-to-one matching between patients in the long-acting anticholinergic and long-acting ␤-agonist cohorts was based on the propensity score and was made only if both scores agreed to within a "caliper" of 0.2 times the SD of the scores. Matching on the propensity score allows unbiased estimation of the treatment effect, to the extent that unmeasured confounders are correlated with the measured covariates. Matching also restricts the analysis to those who are eligible to receive either treatment. Patients were also matched on the basis of age (Ϯ1 year), sex, asthma status, and number of COPD medication prescriptions filled in the previous year. Each matched pair was unique; data from unmatched patients were excluded.
After matching, the 2 treatment groups were compared with respect to each of the measured covariates to determine the adequacy of the model used to estimate the propensity score. A properly constructed propensity score ensures that the 2 matched treatment groups are comparable with respect to all of the measured covariates. Appendix Table 2 shows the standardized between-group differences and P values before and after matching. After matching, all standardized differences were less than 10%, and all P values were far removed from statistical significance, which indicates good balance.
Cox proportional hazards survival analysis was used to compare outcomes for patients in the long-acting anticholinergic treatment cohort with those in the long-acting ␤-agonist cohort, taking membership in a matched pair into account.
Our primary analysis found improved outcomes among patients initially treated with a long-acting ␤-agonist compared with those initially treated with a long-acting anticholinergic ( Table 2 ). To supply context for the reported hazard ratios, Table 2 also presents the absolute difference in survival at 3 years. Appendix Table 3 contains more complete information, showing the percentage of patients in the group initially treated with long-acting ␤-agonists who survived to the end of each of the 5 years, and the survival difference between the treatment groups. The percentage of patients who survived in the longacting anticholinergic cohort can be calculated as the percentage who survived in the long-acting ␤-agonist cohort minus the difference in survival.
Calibrated Propensity Score Analysis
As a check that variables not available in the health administrative data were balanced between the treatment groups, we performed a sensitivity analysis by using propensity score calibration (17). A representative subcohort of 694 patients (250 from the long-acting ␤-agonist cohort and 444 from the long-acting anticholinergic cohort) participated in the Canadian Community Health Survey and had data on smoking status, including exposure to secondhand smoke, body mass index, immigration status, and self-reported health, to augment the data from their original health administrative variables. A gold standard propensity score was calculated for these patients, on the basis of their original data plus the additional data. This gold standard score was compared with their previous propensity score, using ordinary leastsquares regression, to obtain the relationship between the 2 scores. The resulting equation was then used to transform the propensity scores of all study patients (not just those with additional data) into gold standard scores. Finally, the matching and outcome analyses were repeated, as with the primary analysis. Results of the calibrated propensity score analysis were consistent with the main analysis (Appendix Table 6 ).
Additional Sensitivity Analyses
We performed several additional analyses to check the robustness of the results. Appendix Tables 4 to 8 provide supporting information and results from these analyses.
The analyses were repeated by using a standard proportional hazards regression that adjusted for all covariates rather than the matched propensity score analysis ( Table 2) . Appendix Table 5 presents the hazard ratios for each covariate in this analysis.
Annals of Internal Medicine
www.annals.org
Appendix Table 6 presents the results of the propensity score-matched analysis, stratified by sex, asthma status, number of COPD prescriptions filled in the previous year, inhaled corticosteroid use, and a diagnosis of congestive heart failure. In each stratified analysis, long-acting ␤-agonists continued to be associated with improved survival.
Appendix Table 7 provides the results obtained when all analyses (calculation of the propensity score, matching, and the matched proportional hazards regression) were repeated with the inclusion of outcomes that occurred within 7 days of the index prescription being filled. Including these outcomes did not significantly change the study results.
A time-on-treatment analysis of the effect of medication exposure confirmed the primary findings of better survival in patients who were initially prescribed a long-acting ␤-agonist (Table 4). Appendix Table 8 provides information on the number of person-years and percentage of total person-years spent receiving a long-acting ␤-agonist or long-acting anticholinergic in each of the treatment groups in each year of follow-up. It also provides information about medication crossover and inhaled corticosteroid use during the follow-up period. Adherence to the index medication was not optimal in either medication group, and patients commonly received the nonindex medication. Patients who received a long-acting anticholinergic were more adherent and less likely to have received a long-acting ␤-agonist during the follow-up period than vice versa. They were also less likely to have received an inhaled corticosteroid.
Accounting for Potential Misclassification
The validated case definition of COPD based on health administrative data had a positive predictive value of 0.86 when applied to patients aged 65 years or older (9) . This means that an estimated 14% of those included in our analysis may not have had COPD. The inclusion of misclassified patients in the cohort could have led to incorrect results in 2 ways. First, the misclassified patients could have been more (or less) healthy than those correctly identified and could have been concentrated in 1 of the 2 treatment groups, thus contributing to better (or worse) outcomes in that group. Second, misclassification could have resulted in an apparent increase in the precision of results, thus decreasing the P value and narrowing the CI for the estimated hazard ratios. To determine how each of these might have influenced the results, we estimated the true hazard ratio and its CI under a range of assumptions about the health of patients who were misclassified relative to those who truly had COPD and the effect of misclassification on the precision of the SE.
Appendix Table 9 shows that our results could be explained if misclassification resulted in sufficiently healthier patients in the long-acting ␤-agonist group (for example, because they had asthma, which commonly has lower mortality than COPD) or sufficiently sicker patients in the long-acting anticholinergic group (for example, because their true disease was not being recognized or treated properly). Under the assumptions that all patients misclassified as having COPD were in the long-acting ␤-agonist group and that they were 30% less likely to die (1.0 Ϫ 0.70 ϭ 0.3, or 30%) than those with true COPD, the true hazard ratio would be 1.04 (CI, 1.00 to 1.09). Although the point estimate for the hazard ratio is still greater than 1.0, the lower bound of the CI is compatible with no drug difference (the P value for the comparison would no longer be statistically significant). Likewise, if all misclassified patients were in the long-acting anticholinergic group and were 30% more likely to die, the lower bound of the CI for the true hazard ratio would be 1.00. The assumption that all misclassified patients are in the same treatment group is conservative because increased inequality in the distribution of the misclassified patients leads to lower true hazard ratios. Finally, placing all patients who were misclassified in the long-acting ␤-agonist group and assuming a 20% reduction in the risk for death meant that misclassification would have had to decrease the observed SE of the estimate by more than 50% to widen the true CI to include a value of 1.0. ACE ϭ angiotensin-converting enzyme; COPD ϭ chronic obstructive pulmonary disease. * Patients were also categorized by the area of Ontario in which they lived. † Odds ratio from the logistic regression model predicting the probability that a patient's prescription was for a long-acting anticholinergic rather than a long-acting ␤-agonist. ‡ Testing the hypothesis that the odds ratio is 1.00. § Reference category is rural. In Ontario, primary care is provided by family and general physicians, and specialist COPD care is usually provided by pulmonologists, general internists, or geriatricians. ¶ Number of prescriptions for long-or short-acting ␤-agonists, long-or short-acting anticholinergics, inhaled corticosteroids, oral corticosteroids, methylxanthine, or respiratory antibiotics. ** As indicated by Johns Hopkins Collapsed Ambulatory Diagnostic Groups (13). † † Pneumonia, influenza, or acute bronchitis. ‡ ‡ Acute myocardial infarction, congestive heart failure, ischemic heart disease, cardiac arrhythmia, or cerebrovascular disease. ACE ϭ angiotensin-converting enzyme; COPD ϭ chronic obstructive pulmonary disease. * Patients were also categorized by the area of Ontario in which they lived. † Testing the hypothesis of no difference between the 2 medication cohorts. ‡ In Ontario, primary care is provided by family and general practitioners, and specialist COPD care is usually provided by pulmonologists, general internists, or geriatricians. § Number of prescriptions for long-or short-acting ␤-agonists, long-or short-acting anticholinergics, inhaled corticosteroids, oral corticosteroids, methylxanthine, or respiratory antibiotics. As indicated by Johns Hopkins Collapsed Ambulatory Diagnostic Groups (13). ¶ Pneumonia, influenza, or acute bronchitis. ** Acute myocardial infarction, congestive heart failure, ischemic heart disease, cardiac arrhythmia, or cerebrovascular disease. COPD ϭ chronic obstructive pulmonary disease. * Reflects the risk in the long-acting anticholinergic cohort compared with the long-acting ␤-agonist cohort. Hazard ratios are adjusted for membership in a matched pair. Members of the long-acting anticholinergic and long-acting ␤-agonist cohorts were matched by using propensity score and, where appropriate, age, sex, asthma status, and number of COPD medications. † Testing the hypothesis that the hazard ratio is 1.00. ‡ Reflects the risk in the long-acting anticholinergic cohort compared with the long-acting ␤-agonist cohort. Hazard ratios are adjusted for all variables. § Number of prescriptions for long-or short-acting ␤-agonists, long-or short-acting anticholinergics, inhaled corticosteroids, oral corticosteroids, methylxanthine, or respiratory antibiotics. Analysis used 7425 matched pairs not receiving inhaled corticosteroids and 3643 matched pairs receiving inhaled corticosteroids. ¶ Analysis used 6013 matched pairs with congestive heart failure and 2618 matched pairs without congestive heart failure. COPD ϭ chronic obstructive pulmonary disease. * Reflects the risk in the long-acting anticholinergic cohort compared with the long-acting ␤-agonist cohort. Hazard ratios are adjusted for membership in a matched pair. Members of the long-acting anticholinergic and long-acting ␤-agonist cohorts were matched by using propensity score, age, sex, asthma status, and number of COPD medications. † Testing the hypothesis that the hazard ratio is 1.00. ‡ Pneumonia, influenza, or acute bronchitis. § Congestive heart failure, ischemic heart disease (including acute myocardial infarction), cardiac arrhythmia, or cerebrovascular disease. 
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